Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
申请人:Chang Han-Ting
公开号:US20070135385A1
公开(公告)日:2007-06-14
Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.
AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS
申请人:Chang Han-Ting
公开号:US20090239896A1
公开(公告)日:2009-09-24
Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. The compounds include azaindoles of the formula below [insert FIG.
6
c
] in which at least one of CR4, CR5, CR6 and CR7 is replaced by N, and the groups R1-R7 are defined as in claim
1.
Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
申请人:Chang Han-Ting
公开号:US20070135383A1
公开(公告)日:2007-06-14
The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.